MDMA-Assisted Therapy vs Psilocybin-Assisted Therapy
A side-by-side comparison of recorded mechanisms, evidence review status, related condition topics, and philosophical roots.
At a glance
Source checks, condition-specific assessments and expert review are separate steps. Each assessment applies only to its stated population and use. Topic links do not establish comparative effectiveness.
MDMA-Assisted Therapy
- Tradition
- Psychedelic
- Founder
- MAPS / Mithoefer (2021)
- Review status
- 4 source checks available
- Official sources
Guidelines and official sources (4)
3 clinical guideline checks · 1 regulatory source check
Read the recommendation and its scope. A source may discuss an approach without recommending it.
- NDA 215455: midomafetamine complete response letter
Not a treatment recommendation
The letter verifies the 2024 nonapproval decision and identifies safety reporting, durability and bias concerns. Psychotherapy-contribution questions appear separately as additional comments.
Scope: Midomafetamine application NDA 215455 for PTSD
- Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder
Insufficient evidence for or against
VA/DoD finds insufficient evidence for or against MDMA-assisted psychotherapy. The guideline’s evidence cutoff precedes later trials and regulatory decisions.
Scope: MDMA-assisted psychotherapy for adults with PTSD; evidence reviewed through May 2022.
- Management of Major Depressive Disorder
Recommendation against the stated use
VA/DoD strongly recommends against MDMA for MDD outside research. This 2022 guideline used evidence through January 2021; it does not assess later trials or every diagnosis.
Scope: MDMA for MDD outside research settings.
- Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder in Adults
Insufficient evidence for or against
APA finds insufficient evidence for or against this intervention in the reviewed comparisons.
Scope: Adults with PTSD; MDMA-assisted psychotherapy versus the inactive or low-dose active comparators reviewed.
- NDA 215455: midomafetamine complete response letter
- Focus
- Experiential + Processing
- Format
- Individual (co-therapist)
- Duration
- Short (3 sessions)
Psilocybin-Assisted Therapy
- Tradition
- Psychedelic
- Founder
- Griffiths / Carhart-Harris (2016)
- Review status
- 1 condition assessment available
- Official sources
Guidelines and official sources (3)
2 clinical guideline checks · 1 regulatory source check
Read the recommendation and its scope. A source may discuss an approach without recommending it.
- FDA accelerates action on treatments for serious mental illness following Executive Order
Not a treatment recommendation
FDA announced priority vouchers for psilocybin studies in April 2026. This establishes development activity, not approval or psychotherapy endorsement.
Scope: Companies studying psilocybin for TRD and MDD
- Management of Major Depressive Disorder
Recommendation against the stated use
VA/DoD strongly recommends against psilocybin for MDD outside research. This 2022 guideline used evidence through January 2021 and does not review subsequent trials.
Scope: Psilocybin for MDD outside research settings
- Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder
Discussed in the source
VA/DoD finds insufficient evidence for or against psilocybin for PTSD. The statement does not separately establish a psychotherapy-protocol recommendation.
Scope: Psilocybin pharmacotherapy for adult PTSD; evidence reviewed through May 2022.
- FDA accelerates action on treatments for serious mental illness following Executive Order
- Focus
- Experiential + Processing
- Format
- Individual
- Duration
- Short (1-3 doses)
Condition-specific assessments
Each conclusion applies to the population and use described. These source-based assessments do not certify the full entry or replace expert clinical review.
Existential & Meaning-Making Concerns
Population and scope: Carefully selected adults with a potentially life-threatening cancer diagnosis and anxiety/mood symptoms, receiving psilocybin with substantial preparation, monitored sessions and follow-up support.
Randomized studies
Griffiths et al. (2016) randomized dose order in a crossover study: 56 people were assigned and 51 completed at least one session. Higher-dose treatment favored several mood and existential outcomes compared with the very-low-dose condition, including life meaning and death acceptance. After crossover at five weeks, the six-month observations lacked an unexposed comparison. The small, predominantly White, highly educated sample, expectancy and masking limits, and intensive support restrict generalization. Transient anxiety, psychological distress and blood-pressure increases occurred. This is a trial-design assessment for that supervised research context, not a guideline endorsement or evidence for all meaning-making concerns or unsupervised use.
Source assessment dated
How they work
MDMA-Assisted Therapy
Core mechanism: MDMA reduces the fear response and increases trust and empathy, making it possible to stay with trauma material inside the therapeutic relationship
Ontology: PTSD maintained by overwhelming fear that prevents therapeutic engagement; MDMA lowers this barrier pharmacologically
Psilocybin-Assisted Therapy
Core mechanism: Psilocybin disrupts default mode network activity; on the standard account the mystical-type experience this can occasion is what produces lasting shifts in perspective and meaning, though whether that experience is necessary to the effect is actively disputed
Ontology: Rigid self-referential processing (depression) or compulsive patterns maintained by entrenched neural networks
Related condition topics
These editorial cross-references organize reading. A shared link does not mean both approaches are effective, recommended, or interchangeable for that condition.
0 shared · 2 MDMA-Assisted Therapy-only · 3 Psilocybin-Assisted Therapy-only
Linked only in the MDMA-Assisted Therapy entry
Linked only in the Psilocybin-Assisted Therapy entry
What each assumes — and misses
MDMA-Assisted Therapy
Philosophical roots: Mithoefer (inner healing intelligence); Rogers (organismic wisdom, given conditions); Buber (I-Thou enabled pharmacologically); trauma processing theory
Blind spots: FDA declined approval (2024); methodological concerns about unblinding; not currently legally available outside research
Therapeutic voice: You're safe here. If something difficult comes up, you can move toward it. You don't have to do this alone.
Psilocybin-Assisted Therapy
Philosophical roots: James (mystical experience); Huxley (doors of perception, reducing valve theory); Watts (ego dissolution); Buddhist concepts (non-self, interconnection); Carhart-Harris (entropic brain hypothesis)
Blind spots: Not FDA approved; challenging experiences can be destabilizing; standardization of therapy component still developing
Therapeutic voice: Whatever comes, let it come. Whatever goes, let it go. Trust the process.
Choosing between them
MDMA-Assisted Therapy and Psilocybin-Assisted Therapy both sit within the Psychedelic tradition — they share a worldview about what suffering is and how change happens. Differences are more often about technique and emphasis than about underlying theory.
For deeper coverage: see the full MDMA-Assisted Therapy and Psilocybin-Assisted Therapy pages, or use the interactive comparison tool to add more modalities to this comparison.